Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. Halwani AS, Panizo C, Isufi I, Herrera AF, et al. Leuk Lymphoma 2021 Dec 6:1-13. doi: 10.1080/10428194.2021.2010057.

Read + Share

Amedeo Smart

Independent Medical Education

Halwani AS, Panizo C, Isufi I, Herrera AF, et al. Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. Leuk Lymphoma 2021 Dec 6:1-13. doi: 10.1080/10428194.2021.2010057.
PMID: 34865586